Synapse - Joachim Yahalom

Search Within

Joachim Yahalom

Results (35)

Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy

Meeting Abstract

Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
Blood (2021)

Fulltext@MSK | Save

Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Journal Article

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)

Meeting Abstract

Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
Blood (2020)

Fulltext@MSK | Save

Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
Blood (2020)

Fulltext@MSK | Save

Clinical impact of bridging therapy prior to commercial chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory lymphomas

Meeting Abstract

Imber, B. S.; Perales, M. A.; Flynn, J.; Ruiz, J. D.; Devlin, S.; Alarcon Tomas, A.; Hajj, C.; Batlevi, C. L.; Dahi, P. B.; Lin, R. J.; more...
Blood (2020)

Fulltext@MSK | Save

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

Journal Article

Sermer, D.; Batlevi, C.; Lia Palomba, M.; Shah, G.; Lin, R. J.; Perales, M. A.; Scordo, M.; Dahi, P.; Pennisi, M.; Afuye, A.; more...
Blood Advances (2020)

Fulltext@MSK | Save

Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy

Journal Article

Imber, B. S.; Sadelain, M.; DeSelm, C.; Batlevi, C.; Brentjens, R. J.; Dahi, P. B.; Giralt, S.; Park, J. H.; Sauter, C.; Scordo, M.; more...
British Journal of Haematology (2020)

Fulltext@MSK | Save

Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
Blood (2019)

Fulltext@MSK | Save

High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
Blood (2019)

Fulltext@MSK | Save

Early experience using radiotherapy as a salvage treatment for relapsed or refractory non-Hodgkin lymphomas following CD19 chimeric antigen receptor modified T-cell therapy

Meeting Abstract

Imber, B.; Palomba, M. L.; DeSelm, C.; Dahi, P. B.; Sauter, C. S.; Scordo, M.; Batlevi, C. L.; Park, J. H.; Shah, G. L.; Giralt, S. A.; more...
Blood (2019)

Fulltext@MSK | Save